Drugs / ABBV-901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07278336 | Nov 2025 → Dec 2028 expected | ovarian cancer | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07278336 ↗ |
| Route | Intravenous | “escalating doses of intravenous (IV) ABBV-901 alone” NCT07278336 ↗ |